{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1"},{"groupId":"OG001","value":"75.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. ORR was calculated as the percent of responders (multiplied by 100). Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \\< 200 mg per 24 hours.","groups":[{"description":"Durvalumab 1500 mg + Daratumumab 16 mg/kg were administered intravenously within a 28-day cycle for a maximum of 60 cycles. POM + DEX could be added to the D2 regimen, at the investigator's discretion, upon confirmed progressive disease for participants who had at least 2 cycles of D2.","id":"OG000","title":"Simon Stage 1: D2 Arm"},{"description":"Durvalumab 1500 mg IV + Daratumumab 16 mg/kg IV + Pomalidomide 4 mg/day Oral + Dexamethasone 40 mg Oral (20 mg for \\> 75 Years Old) administered within a 28-day cycle for a maximum of 22 cycles","id":"OG001","title":"PD3 Arm"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received at least 1 dose of the study medication, and who have measurable disease at baseline and at least 1 postbaseline efficacy assessment.","reportingStatus":"POSTED","timeFrame":"From first dose to up to approximately 66 months","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}